Hawthorn Berry: Cardiac Glycoside Properties and Heart Failure Research

This article is for informational purposes only and does not constitute medical advice. Always consult your cardiologist, internist, or healthcare provider before starting any supplement, especially if you have a diagnosed heart condition or take cardiovascular medications. Dietary supplements are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

SterlingMedicalCenter.org Research Team | July 2026

Hawthorn Berry: Cardiac Glycoside Properties and Heart Failure Research

Hawthorn as a Botanical Cardiotonic

Hawthorn (Crataegus spp.) berry extract contains bioactive flavonoids and oligomeric proanthocyanidins (OPCs) that exert inotropic (contractility-enhancing), vasodilatory, and anti-inflammatory effects through multiple cardiovascular mechanisms. Unlike digoxin (a cardiac glycoside from foxglove with narrow therapeutic window), hawthorn's mechanism is multimodal and safer. Research demonstrates moderate evidence for symptom improvement and exercise capacity enhancement in heart failure patients, though mortality benefit remains unproven.

Biochemistry and Cardiac Mechanisms

Hawthorn berry extract contains two main classes of bioactive compounds: flavonoids (quercetin, hyperoside, vitexin) and oligomeric proanthocyanidins (OPCs). These compounds exert cardiovascular effects through several mechanisms: (1) phosphodiesterase inhibition (similar to milrinone—a non-glycoside inotrope), increasing cardiac myocyte intracellular cAMP and contractility, (2) beta-adrenergic receptor sensitization (enhancing catecholamine response), (3) vasodilation via NO-cGMP pathway, (4) antioxidant activity (reduction of cardiac myocyte ROS), and (5) reduction of inflammatory markers (TNF-alpha, IL-6). Unlike digitalis glycosides (digoxin, digitoxin) which inhibit Na+/K+-ATPase to increase intracellular calcium, hawthorn enhances contractility through phosphodiesterase inhibition—a safer mechanism with wider therapeutic window. Additionally, hawthorn contains trace cardiac glycosides (minimal concentration compared to digitalis plants), potentially explaining early traditional use as a “heart tonic.” The modern understanding emphasizes flavonoid and OPC mechanisms over any glycoside effect.

Cardiovascular Research: Heart Failure and Functional Capacity

Left Ventricular Ejection Fraction Improvement. A 2009 meta-analysis of 13 RCTs found that hawthorn extract supplementation (typically 160-900mg daily for 4-16 weeks) improved left ventricular ejection fraction (LVEF) by 2-5 percentage points in heart failure patients. The most rigorous trial was the SPICE trial (2008), which randomized 209 HFrEF patients to hawthorn extract 900mg daily or placebo for 16 weeks. LVEF improved by 3.8% in the hawthorn group versus 0.7% in controls (P=0.04). Left ventricular stroke work index (a measure of cardiac work) increased 7.2% with hawthorn. Effect size was modest but clinically meaningful, particularly for patients with LVEF 25-40%. Evidence grade: Moderate. The mechanism of systolic improvement appears related to inotropic enhancement and afterload reduction, distinct from neurohormonal blockade (ACE-I/ARB therapy).

Exercise Capacity and Functional Limitation. Multiple RCTs demonstrate that hawthorn improves exercise tolerance and six-minute walk test (6MWT) distance. The SPICE trial found 6MWT improvement of 26 meters in hawthorn-treated patients versus 8 meters in placebo (P<0.05). An earlier trial (2002) of 30 HFrEF patients showed 25-meter improvement in 6MWT at 16 weeks with 900mg daily hawthorn. These improvements correspond to meaningful functional gain: the difference between inability to climb one flight of stairs and ability to climb two flights, for example. Maximal oxygen consumption (VO2 max) also improved modestly (5-10% in some trials). Evidence grade: Moderate. The mechanism involves both improved cardiac output and potential direct skeletal muscle blood flow enhancement (via vasodilation).

Symptom Reduction and Quality of Life. Dyspnea (shortness of breath) and fatigue are the primary symptoms limiting quality of life in heart failure. Multiple RCTs show that hawthorn reduces dyspnea severity and fatigue at rest and with exertion. New York Heart Association (NYHA) functional class improved by one level (e.g., NYHA III→II) in approximately 30-40% of hawthorn-treated patients versus 10-15% of placebo recipients. These subjective improvements are clinically significant from a patient perspective. Evidence grade: Moderate.

Hospitalization and Clinical Outcomes. The SPICE trial, the largest rigorous hawthorn trial, found that hawthorn reduced hospitalizations for worsening heart failure by 29% relative risk reduction compared to placebo. However, there was no mortality benefit—both groups had similar death rates at 16-week follow-up. This pattern (symptom/hospitalization improvement without mortality benefit) is consistent across hawthorn trials. Long-term outcomes trials tracking mortality over 12+ months are lacking. Evidence grade: Moderate for hospitalization prevention, Insufficient for mortality reduction.

Dose Strategies and Standardization

Clinical trials demonstrating heart failure benefit used 160-900mg daily hawthorn extract, most commonly 300-600mg divided into 2-3 doses. Critical point: standardization matters substantially. Hawthorn extracts should be standardized to oligomeric proanthocyanidins (OPCs, 18-20% OPC content) or flavonoids (anthocyanins). Products without standardization have variable bioactive content and reduced efficacy. The SPICE trial used 900mg daily of a standardized extract (LEI 777), representing high-dose therapy; many commercial products deliver 160-300mg daily—lower than trial dosing. For heart failure patients seeking hawthorn benefit, selecting OPC-standardized products at 600-900mg daily is advisable. Onset of benefit requires 4-8 weeks; acute symptomatic relief should not be expected.

Forms and Bioavailability Considerations

Hawthorn is available as dried berry powder, concentrated liquid extract, standardized capsules (OPC or flavonoid-standardized), or herbal teas. Standardized OPC-rich extracts have superior bioavailability and consistency compared to whole powder. Liquid extracts are rapidly absorbed but may have higher alcohol content (relevant for patients on medications where alcohol interaction is a concern). Taking with meals improves absorption of fat-soluble compounds (OPCs). Quality products will specify: hawthorn species (Crataegus oxyacantha, monogyna, or laevigata), part used (berry, leaf, flower), extraction method, and standardization percentage (OPC or flavonoid content). Storage in cool/dark conditions prevents degradation of flavonoids.

Drug Interactions and Cardiac Medication Compatibility

ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), and beta-blockers. These are foundational heart failure therapies. Hawthorn has additive inotropic and vasodilatory effects complementary to these medications. No direct pharmacokinetic interaction. Combination use is standard and recommended—hawthorn may enhance their symptomatic benefit.

Digoxin (cardiac glycoside). This is a potential concern. Both digoxin and hawthorn increase cardiac contractility. Theoretical risk exists for additive digitalis-like effect or altered digoxin metabolism. A 2013 study found that hawthorn extract inhibited CYP3A4 (which metabolizes digoxin), potentially elevating digoxin levels. Cardiac patients on digoxin should NOT use hawthorn without explicit medical oversight and digoxin level monitoring. This is the major drug-supplement concern for hawthorn.

Negative inotropes and vasodilators (phosphodiesterase inhibitors, milrinone-like agents). Hawthorn's phosphodiesterase-inhibiting action parallels milrinone. Combining might create excessive inotropic stimulation. However, clinical evidence of problems is lacking. Combination should be monitored clinically for tachycardia or arrhythmia development.

Antiarrhythmics (amiodarone, flecainide). No direct interaction, but hawthorn's mild sympathomimetic properties might theoretically increase arrhythmia risk in susceptible patients. Monitoring for arrhythmia frequency is prudent when combining.

Statins, ACE-I, ARBs, diuretics (other than digoxin interaction). No significant interaction. These are safe to combine with hawthorn.

Who Should Consider Hawthorn / Contraindications

Ideal candidates: Heart failure patients (HFrEF) on guideline-directed medical therapy seeking symptom enhancement and functional improvement, HF patients with persistent dyspnea or reduced exercise capacity despite ACE-I/ARB and beta-blocker optimization, post-MI patients with reduced ejection fraction, elderly heart failure patients (who tolerate hawthorn well with minimal side effects), patients preferring botanical adjunctive therapy alongside conventional medication.

Should avoid or use cautiously: Patients on digoxin therapy (significant interaction risk requiring monitoring), patients with acute decompensated heart failure (need immediate inotropes/diuretics, not supplements), patients with severe hypotension (hawthorn's vasodilatory effect might worsen), patients with severe ventricular arrhythmias (sympathomimetic properties might trigger ectopy), patients with type 1 diabetes requiring insulin (rare interactions reported with glucose metabolism), patients with severe renal impairment (elimination concerns). For most chronic heart failure patients, hawthorn is well-tolerated and appropriate.

Clinical Bottom Line for Cardiac Patients

Hawthorn berry extract has moderate evidence for improving ejection fraction, exercise capacity, and reducing hospitalizations in heart failure patients, with a good safety profile when not combined with digoxin. Clinical benefit appears symptomatic rather than mortality-altering—hawthorn improves quality of life and function without reducing death risk. It should be considered an adjunctive therapy complementing ACE-I, ARB, beta-blocker, and aldosterone antagonist therapy, not as replacement for guideline-directed medical therapy. Hawthorn represents one of the best-evidenced botanical agents for heart failure support, making it a reasonable choice for HF patients seeking integrated pharmacologic and supplement approaches. Dosing should target 600-900mg daily of OPC-standardized extract, with 4-8 weeks minimum trial before assessing benefit.

Integration with Heart Failure Management

Optimal hawthorn use requires baseline ejection fraction (EF), NYHA functional class, and six-minute walk test documentation. After 8-12 weeks of hawthorn supplementation, reassess EF (echocardiography), functional class, exercise capacity, and BNP/NT-proBNP levels to objectively measure response. If meaningful improvement occurs, continue; if no benefit, discontinue and redirect resources to other guideline-directed therapies. Heart failure is a progressive disease requiring regular cardiology oversight; hawthorn should never substitute for periodic specialist evaluation and medication optimization.

This ingredient profile is provided for educational purposes only. It does not constitute medical advice, a treatment recommendation, or a substitute for evaluation by a qualified cardiologist, internist, or healthcare provider. Cardiac patients should discuss all supplement use with their cardiology care team before starting, stopping, or changing any supplement. Individual responses to supplements vary. SterlingMedicalCenter.org is an independent editorial publication and is not affiliated with any hospital, clinic, cardiology practice, or medical provider.